Hints and tips:
Related Special Reports
...Shah Capital now owns 6.7 per cent of Novavax, having first bought into the company in the last quarter of 2022....
...Any rumours that the company is at risk of defaulting are “flatly untrue”, he said....
...Shockwave’s technology has treated approximately 400,000 patients globally, the company said....
...Our mutual goal needs to be that this will remain the case.”...
...Illumina said the company agreed “with the advocate general that the European Commission’s assertion of jurisdiction over this merger was improper”. Illumina bought Grail in 2021....
...In the past decade, the company rolled out four BlackRock-branded fixed income SMAs and four equity SMAs, according to data from the company’s website....
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
...Franklin Templeton’s experience suggests few investors are bothered about seeing their ownership of a mutual fund on a blockchain....
...ETFs accounted for 51 per cent of underlying assets at the end of last year, up from 46.7 per cent in early 2022, according to data from Broadridge Financial Solutions, a financial technology company, which...
...Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded....
...Peter Maag, Kyverna chief executive, said it was a “stellar outcome” and that he was particularly encouraged by the level of interest from large generalist mutual fund investors, rather than only healthcare...
...MSIM launched its ETF business a year ago, and in October filed plans to carry out its first mutual fund-to-ETF conversions....
...In July 2022, the firm secured a €7bn pool to lend to European midmarket companies, the largest fund it has ever raised....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...Pfizer shares tumbled more than 8 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid...
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
Case studies in best practice among general counsel and company legal teams in North America
...Buckley initially joined Vanguard as a research assistant to Jack Bogle, the group’s founder, who pioneered passive investing and the company’s unusual mutual structure....
...Hours later, the two companies issued a mutual statement terminating the deal, citing the regulatory challenges. Adobe will pay Figma $1bn in a termination fee under the terms of the merger agreement....
...Mutual funds have enabled millions to invest in the stock market since they were introduced 100 years ago, but newer, nimbler products are reshaping asset management....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...“Geopolitical friction and complexity are at an all-new level,” says Anne Madden, general counsel at technology and engineering company Honeywell....
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
...Last month, State Street and Vanguard estimated that none of their ETFs would pass along capital gains, the companies’ respective websites show....
...ETF promoters in Europe gathered €17.8bn of net new money last month, far above the sector’s rolling 12-month average of €12bn, the research company found....
International Edition